Cited by 321Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Open access

Ferris, Robert L., Jaffee, Elizabeth M., Ferrone, Soldano·2010·Journal of Clinical Oncology

DOI 10.1200/jco.2009.27.6360PMC PMC2954137

Open this paper in CoChat — free account

Abstract

PURPOSE: Tumor antigen (TA) -targeted monoclonal antibodies (mAb), rituximab, trastuzumab, and cetuximab, are clinically effective for some advanced malignancies, especially in conjunction with chemotherapy and/or radiotherapy. However, these results are only seen in a subset (20% to 30%) of patients. We discuss the immunologic mechanism(s) underlying these clinical findings and their potential role in the variability in patients' clinical response. METHODS: We reviewed the evidence indicating that the effects of TA-targeted mAb-based immunotherapy are mediated not only by inhibition of signaling pathways, but also by cell-mediated cytotoxicity triggered by the infused TA-targeted mAb. We analyzed the immunologic variables that can influence the outcome of antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro and in animal model systems. We also analyzed the correlation reported between these variables and the clinical response to mAb-based immunotherapy. RESULTS: Of the variables that influence ADCC mediated by TA-targeted mAb, only polymorphisms of Fcγ receptors (FcγR) expressed by patients' lymphocytes were correlated with clinical efficacy. However, this correlation is not absolute and is not observed in all malignancies. Thus other variables may be responsible for the antitumor effects seen in mAb-treated patients. We discuss the evidence that triggering of TA-specific cellular immunity by TA-targeted mAb, in conjunction with immune escape mechanisms used by tumor cells, may contribute to the differential clinical responses to mAb-based immunotherapy. CONCLUSION: Identification of the mechanism(s) underlying the clinical response of patients with cancer treated with TA-targeted mAb is crucial to optimizing their application in the clinic and to selecting the patients most likely to benefit from their use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.27.6360

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
IgG Fc Receptors
Ravetch, J. V., & Bolland, S. M. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,687
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,324
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,319
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,272
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,112

Flagged first, then by citations

Show all 122 references

Research works printed but not linked: 9

Abes R, Blood
Reilly RT, 2001, Cancer Res, 61, 880
Sharafanski M, Head and Neck
Valentini AM, 2008, Curr Opin Mol Ther, 10, 124
Zhao WP, 2009, Oncol Rep, 21, 1405
Whiteside TL, 1996, Anticancer Res, 16, 2357
Ugurel S, 2002, Onkologie, 25, 129
Li D, 2002, Cancer Res, 62, 4023
10.1158/1078-0432.CCR-05-2750 · DOI

Sorted by citations

Items 201–300 of 321

Translational research of new developments in targeted therapy of colorectal cancer
Yang, L., Atakhanova, N. E., Arellano, M. T. C., Mohamed, M. Y., Hani, T., Fahdil, A. A., Castillo-Acobo, R. Y., Juyal, A., Hussein, A. K., Amin, A. H., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154888 · Cited by 14
Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination
Rha, S. Y., & Chung, H. C. (2023) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2023.23.e6 · Cited by 14
The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model
Örbom, A., Eriksson, S. E., Elgström, E., Ohlsson, T. G., Nilsson, R., Tennvall, J., & Strand, S. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.117028 · Cited by 13
The Role of Targeted Therapy in the Management of Sinonasal Malignancies
Kashat, L., Le, C. H., & Chiu, A. G. (2017) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2016.12.016 · Cited by 13
Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era
Klener, P., Etrych, T., & Klener, P. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171006144725 · Cited by 14
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity
Sustmann, C., Dickopf, S., Regula, J. T., Kettenberger, H., Mølhøj, M., Gassner, C., Weininger, D., Fenn, S., Manigold, T., Kling, L., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1661736 · Cited by 12
Domain Recognition of the ING1 Tumor Suppressor by a Panel of Monoclonal Antibodies
Suzuki, K., Boland, D., Gong, W., & Riabowol, K. T. (2011) · Hybridoma · doi:10.1089/hyb.2010.0124 · Cited by 12
Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice
Lalami, Y., & Awada, A. H. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.001 · Cited by 13
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb
Eriksson, S. E., Bäck, T. A., Elgström, E., Jensen, H. J., Nilsson, R., Lindegren, S., & Tennvall, J. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-23 · Cited by 12
Re-purposing cancer therapeutics for breast cancer immunotherapy
Emens, L. A. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1247-z · Cited by 11
Antibody Therapies in Cancer
Wang, S., & Jia, M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7555-7_1 · Cited by 11
Monoclonal Antibodies for Cancer Immunotherapy
Zarnani, A., Bozorgmehr, M., Shabani, M., Leila, B. Y., Ghaemimanesh, F., & Jeddi‐Tehrani, M. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_16 · Cited by 11
Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors
Wang, Q., Ding, H., Liu, B., Li, S.-H., Li, P., Ge, H., & Zhang, K. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2271 · Cited by 11
Development of Monoclonal Antibodies in China: Overview and Prospects
Zhang, M., Lu, J., Wang, L., Gao, Z.-C., Hu, H., Ung, C. O. L., & Wang, Y. (2015) · BioMed Research International · doi:10.1155/2015/168935 · Cited by 10
Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma
Rafei, H., Haroun, F., & Tabbara, I. A. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000506 · Cited by 10
Radiothérapie et immunomodulation : mise au point sur les données expérimentales
Deutsch, É., Lévy, A., & Chargari, C. (2015) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2015.05.018 · Cited by 9
Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck
Machiels, J., & Schmitz, S. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.07.007 · Cited by 9
Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
Repetto‐Llamazares, A. H. V., Abbas, N., Bruland, Ø. S., Dahle, J., & Larsen, R. H. (2014) · PubMed · Cited by 9
Limits of Conventional Cancer Chemotherapy
Mross, K. B., & Kratz, F. (2011) · doi:10.1002/9783527634057.ch1 · Cited by 9
Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy
Yang, S., Yang, Y., Fang, Y., Zhou, Q., Sun, W., Zhang, Z., Yuan, W., & Li, Z. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08254-z · Cited by 10
Lonely killers
Fernández‐Marrero, Y., & López‐Requena, A. (2011) · mAbs · doi:10.4161/mabs.3.6.17770 · Cited by 8
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies
Demel, I., Kořı́stek, Z., Motais, B., Hájek, R., & Jelı́nek, T. (2022) · American Journal of Hematology · doi:10.1002/ajh.26529 · Cited by 7
Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with 177 Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model
Eriksson, S. E., Ohlsson, T. G., Nilsson, R., & Tennvall, J. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2011.1132 · Cited by 7
Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges
Oh, B. L. Z., Chan, L. W. Y., & Chai, L. Y. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1044946 · Cited by 7
Global research trends in immunotherapy for head and neck neoplasms: A scientometric study
Jiang, Z., Wu, C., Zhao, Y., Zhan, Q., Wang, K., & Li, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15309 · Cited by 7
Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its Fragment in an Immunocompetent Mouse Model
Rabasa, A., Mesa, J. E. G., Rodríguez‐Vera, L., López, A., Ramírez, B. S., & Hidalgo, G. G. (2012) · ISRN Pharmacology · doi:10.5402/2012/417515 · Cited by 7
Immune therapy in multiple myeloma.
Luptakova, K., & Avigan, D. (2015) · PubMed · Cited by 7
Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab
Ladányi, A., Kapuvári, B., Papp, E., Tóth, E., Lövey, J., Horváth, K., Gődény, M., & Remenár, É. (2018) · Head & Neck · doi:10.1002/hed.25546 · Cited by 7
Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity
Kawaguchi, K., Suzuki, E., Nishie, M., Kii, I., Kataoka, T. R., Hirata, M., Inoue, M., Pu, F., Iwaisako, K., Tsuda, M., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2002-2 · Cited by 7
Intraperitoneal Radioimmunotherapy: Auger Electron Emitters for Solid Tumors
Baranowska‐Kortylewicz, J. (2011) · Immunotherapy · doi:10.2217/imt.11.11 · Cited by 7
Monoclonal Antibodies for Cancer Immunotherapy
Zarnani, A., Jafari, D., Bozorgmehr, M., Shabani, M., Leila, B. Y., Ghaemimanesh, F., & Jeddi‐Tehrani, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_15 · Cited by 6
Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond
Höchst, B., & Knolle, P. A. (2017) · ORL · doi:10.1159/000455810 · Cited by 6
Immunotherapeutic Strategies for Head and Neck Cancer
Buchwald, Z. S., & Schmitt, N. C. (2021) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2021.04.004 · Cited by 6
Microcirculation density and maturity in uterine and soft tissue leiomyosarcomas: an immunohistochemical study.
Caraffi, S. G., Corradi, D., Campanini, N., Govoni, P., Rocchi, L., Perris, R., & Mangieri, D. (2015) · PubMed · doi:10.14670/hh-30.69 · Cited by 6
Recent advances and future trends in the targeted therapy of metastatic gastric cancer
Al‐Batran, S., & Werner, D. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.902304 · Cited by 6
Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance
Zahavi, D. J., Erbe, R., Zhang, Y., Guo, T. W., Malchiodi, Z. X., Maynard, R. E., Lekan, A. A., Gallagher, R. I., Wulfkuhle, J. D., Petricoin, E. F., et al. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2269637 · Cited by 6
Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation
Seledtsov, V. I., Seledtsova, G. V., Darinskas, A., & von Delwig, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167724 · Cited by 6
Effector and cytolytic function of natural killer cells in anticancer immunity
Karmakar, S., Mishra, A., Pal, P., & Lal, G. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad126 · Cited by 5
Engineering natural killer cells for cancer immunotherapy
Liu, Z., Liu, B., Fang, Y., Zhong, Q., Zhong, Y., Lao, Y., Lv, S., Xie, X., Yu, T., Zhou, X., et al. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102681 · Cited by 5
Cancer: Towards a general theory of the target
Vincent, M. D. (2017) · BioEssays · doi:10.1002/bies.201700059 · Cited by 5
Are Immune Signatures a Worthwhile Tool for Decision Making in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer?
Foekens, J. A., Martens, J. W. M., & Sleijfer, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5058 · Cited by 5
Innovative immunotherapy approaches: harnessing synergy of dual checkpoint blockade in oncology
Shaik, R., Mounika, V., Badampudi, S., Jabeen, A., Hamzah, M. A., Zehra, F. U., Unnisa, A. Z., Mohammed, J. S., & Azeeza, S. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04884-4 · Cited by 5
Trispecific SEED antibodies engineered for neutrophil-mediated cell killing
Natale, V., Heves, G., Stadlbauer, K., Rüker, F., Siegmund, V., Pekar, L., Zielonka, S., Toleikis, L., Becker, S., & Wozniak‐Knopp, G. (2025) · mAbs · doi:10.1080/19420862.2025.2532851 · Cited by 4
Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors
Furlan, S. N., Mandraju, R., Brewer, T., Roybal, K. T., Troutman, T. D., Hu, W., Palm, N. W., Unni, A. M., & Pasare, C. (2013) · mAbs · doi:10.4161/mabs.27052 · Cited by 4
The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer
Castet, F., Brenes, J., Taberna, M., & Mesı́a, R. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000530 · Cited by 4
Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment
Calderon, M. J. G., González-Marcano, E. B., Carballo, J., & Convit, A. F. (2019) · Oncotarget · doi:10.18632/oncotarget.27283 · Cited by 4
Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805
Ando, M., Nagata, K., Nihira, K., Suzuki, Y., Kanda, Y., Adachi, M., Kubota, T., Kameyama, N., Nakano, M., Ando, H., et al. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.06.007 · Cited by 4
Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence
Wang, Y., Sabbatino, F., Yu, L., Favoino, E., Wang, X., Ligorio, M., Ferrone, S., Schwab, J. H., & Ferrone, C. R. (2013) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-1-4614-7654-2_2 · Cited by 4
Self-citation
Navigating the landscape: A comprehensive overview of computational approaches in therapeutic antibody design and analysis
Yadav, A. J., Bhagat, K., Sharma, A., & Padhi, A. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.011 · Cited by 3
Chemotherapy in Head and Neck Squamous Cell Cancer
Burchhardt, D. M., & Sukari, A. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-27647-2_4 · Cited by 3
Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy
Meenakshi, S., Maharana, K. C., Nama, L., Vadla, U. K., Dhingra, S., Ravichandiran, V., Murti, K., & Kumar, N. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230809110444 · Cited by 3
The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype
Valcenko, A., Zwick, A., Schneider, L., Linxweiler, M., & Lohse, S. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.107042 · Cited by 3
Engineering antibodies with cancer‐associated binding sites
Tian, Y., Pan, Y., Zhang, Y., Wang, F., & Wang, Z. (2024) · BMEMat · doi:10.1002/bmm2.12134 · Cited by 3
Computational and Experimental Evaluation of Linker Peptides and Thioredoxin Fusion Tag in CD20-rituximab Specific Interactions
Damough, S., Alizadeh, R., Komijani, S., Shirin, M., Adeli, A., Mafakher, L., Mahboudi, F., & Talebkhan, Y. (2023) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-134267 · Cited by 3
Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor
Osaki, T., Wang, C., Tachibana, T., Azuma, M., Kitamura, M., & Nakanishi, T. (2015) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2015.0034 · Cited by 3
Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies
van Vloten, J. P., Klafuric, E. M., Karimi, K., McFadden, G., Petrik, J., Wootton, S. K., & Bridle, B. W. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.010 · Cited by 3
Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis
Chen, P., Mao, X., Ma, N., Wang, C., Yao, G., Ye, G., & Zhou, D. (2022) · Medicine · doi:10.1097/md.0000000000029877 · Cited by 3
A therapeutic perspective of cytokines in tumor management
(2014) · Inflammation and Cell Signaling · doi:10.14800/ics.159 · Cited by 2
Effects of epidermal growth factor receptor fusion protein on the cytotoxic activity of SOCS1-silenced dendritic cells in vitro
Jiang, Q., Wang, X., Qian, M., Chen, D., & Xu, Y. (2017) · Oncology Reports · doi:10.3892/or.2017.6160 · Cited by 2
Combination immunochemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis
Xu, Q., Huang, S., & Yang, K. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069047 · Cited by 2
Radiotherapy Upregulates the Expression of Membrane-Bound Negative Complement Regulator Proteins on Tumor Cells and Limits Complement-Mediated Tumor Cell Lysis
Liang, Y., Mai, L., Schneeweiss, J. M., Perez, R. L., Kirschfink, M., & Huber, P. E. (2025) · Cancers · doi:10.3390/cancers17142383 · Cited by 2
Construction of random tumor transcriptome expression library for creating and selecting novel tumor antigens
Zhao, H., Zhao, X., Du, P. F., & Qi, G. (2016) · Tumor Biology · doi:10.1007/s13277-016-5201-0 · Cited by 2
Immunology and Immunotherapy of Breast Cancer
Stagg, J., & Loi, S. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_23 · Cited by 2
Novel syngeneic mouse mammary carcinoma cell lines from aggressive ErbB2/Neu-overexpressing/PTEN-deficient tumors
Wang, Q., Ding, H., WANG, H., Li, P., Liu, B., & Zhang, K. (2014) · Oncology Reports · doi:10.3892/or.2014.3574 · Cited by 2
Human papillomavirus-related oropharyngeal squamous cell carcinoma: a new context for dysphagia rehabilitation
Theurer, J., Yoo, J. J., & Nichols, A. C. (2014) · Current Physical Medicine and Rehabilitation Reports · doi:10.1007/s40141-014-0058-x · Cited by 2
Mining Effective Subsequences with Application in Marketing Attribution
Yin, Z., Li, Y., Mazzoleni, P., & Shen, Y. (2016) · IEEE ... International Conference on Data Mining workshops · doi:10.1109/icdmw.2016.0104 · Cited by 2
Immunotherapeutic approaches in HNSCC
Schmitt, N. C., & Ferris, R. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820679-9.00008-6 · Cited by 2
Self-citation
Approaches to Immunologic Monitoring of Clinical Trials
Butterfield, L. H., Vujanovic, L. N., & Pardee, A. D. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_29 · Cited by 2
Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)
Moy, J. D., & Ferris, R. L. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_14 · Cited by 2
Self-citation
A CHIMERIC RECEPTOR ENABLING ANTIBODY-GUIDED RETARGETING OF CAR T- CELLSPreprint
Vinanica, N., Yeo, J. Q., Hamran, N. A. N., & Campana, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.27.720976 · Cited by 2
Introduction: Leaps and bounds
Tam, K., Ghazizadeh, S., Abemayor, E., & John, M. A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820679-9.00001-3 · Cited by 1
Tumor-microbe transkingdom interactions in cancers at body interfaces: mechanisms of neutrophil lifespan extension and functional reprogramming with therapeutic implications
Mohamed, I., & Lohse, S. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.101065 · Cited by 1
The Immune System in Head and Neck Squamous Cell Carcinoma: Interactions and Therapeutic Opportunities
Serafini, P., & Weed, D. T. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_13 · Cited by 1
Introduction and Background Biology
Fasolo, A., Zambelli, S., & Gianni, L. (2013) · doi:10.1007/978-1-907673-94-8_1 · Cited by 1
Management of dermatological toxicities in patients receiving EGFR inhibitors
Lynch, K. (2012) · Community Oncology · doi:10.1016/j.cmonc.2012.09.008 · Cited by 1
Blockage of EGFR Pathway for Anticancer Therapy in Squamous Cell Carcinoma of the Head and Neck
Schmitz, S., & Machiels, J. (2017) · Springer eBooks · doi:10.1007/978-94-024-1084-6_6 · Cited by 1
Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials
Huang, Y., Chen, W., Teh, B. S., & Butler, E. B. (2015) · Journal of Radiation Oncology · doi:10.1007/s13566-015-0240-5 · Cited by 1
Improving responses to immunotherapy in head and neck squamous cell carcinoma
Ye, W., Schmitt, N. C., Ferris, R. L., & Allen, C. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817868-3.00006-8 · Cited by 1
Self-citation
Cancer Immunotherapy
Ajina, R., Aldeghaither, D. S., Jablonski, S. A., & Weiner, L. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12426-6 · Cited by 2
Strategies for Tracking Immune Surveillance of Tumor Milieu during Angiogenesis
Vemuri, P. K., Nimmagadda, G., Bodiga, S., Bodiga, V. L., Veeravilli, S., & Rao, K. R. S. S. (2021) · International Journal of Life Science and Pharma Research · doi:10.22376/ijpbs/lpr.2021.11.1.l102-106 · Cited by 1
MOLECULAR REGULATION OF THE TUMOR KILLING ACTIVITY OF DENDRITIC CELLS
Hanke, N. T. (2012) · UA Campus Repository (The University of Arizona) · Cited by 1
Antibody therapy of cancer
Gruijs, M. (2023) · doi:10.5463/thesis.272 · Cited by 1
Tumor escape after immunotherapy: implication of hla class i expression in melanoma and bladder tumors
Coca, R. C. (2011) · Institutional Repository of the University of Granada (University of Granada)
Effect of Surface Chemistry on the Immune Responses and Cellular Interactions of Porous Silicon Nanoparticles
Shahbazi, M. (2015) · Työväentutkimus Vuosikirja
Tumours: Targeting of Monoclonal Antibodies for Imaging and Potential for Therapy
Kaur, S., Jain, M., Senapati, S., & Batra, S. K. (2012) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0001428.pub2
Radioimmunotherapy of Metastatic Disease - Studies of Alpha- and Beta-particle-Emitting Radionuclides in a Preclinical Model
Eriksson, S. E. (2013) · Lund University Publications (Lund University)
Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model
Örbom, A., Eriksson, S. E., Elgström, E., Ohlsson, T. G., Nilsson, R., Tennvall, J., & Strand, S. (2013)
Whole-Cell Vaccines
Jelovac, D., & Emens, L. A. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_148
Immune Checkpoint Inhibition in Renal Cell Carcinoma
Mahoney, K. M., Harshman, L. C., Seery, V. J., & Drake, C. G. (2015) · Springer eBooks · doi:10.1007/978-3-319-17903-2_16
Targeted Therapy in Solid Tumors: Head and Neck
Monroe, M. M., & Myers, J. N. (2015) · doi:10.1002/9781118468678.ch22
La réponse immunitaire anti-tumorale dans le cancer du sein : état des lieux et perspectives thérapeutiques
Ladoire, S., Dérangère, V., Arnould, L., Thibaudin, M., Coudert, B. P., Lorgis, V., Desmoulins, I., Chaix, M., Fumoleau, P., & Ghiringhelli, F. (2017) · Annales de Pathologie · doi:10.1016/j.annpat.2016.12.012
Use of the TLR2 ligand polysaccharide krestin to maximize conventional cancer therapy
Gwin, W. R., Standish, L. J., & Disis, M. L. (2017) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2017.1324300
Characterising the phenotype and function of natural killer cells in patients with prostate cancer
Hood, S. P. (2016) · Nottingham Trent University's Institutional Repository (Nottingham Trent Repository)
Monoclonal Antibody Therapy
Mittendorf, E. A., & Prabhakaran, S. (2018) · doi:10.1002/9781118684535.ch2
Human Papillomavirus-Related Head and Neck Cancer
Theurer, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-04702-3_4
Immunotherapy for cancer of the oral cavity and oropharynx. The use of monoclonal antibodies
Hirna, H. A., Kostyshyn, I. D., Rozhko, M. M., & Levandovskyi, R. A. (2020) · Bukovinian Medical Herald · doi:10.24061/2413-0737.xxiv.2.94.2020.61
Peculiarities of the combined course of chronic ischemic heart disease and type 2 diabetes mellitus (literature review)
Ілащук, Т. О., & Горевич, С. С. (2020) · Bukovinian Medical Herald · doi:10.24061/2413-0737.xxiv.2.94.2020.62
Immunopathology as a Basis for Immunotherapy of Head and Neck Squamous Cell Carcinoma
Qian, X., Hoffmann, T. K., Kaufmann, A. M., & Albers, A. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_13
Introduction and background biology
Fasolo, A., & Gianni, L. (2016) · Springer eBooks · doi:10.1007/978-3-319-28216-9_1
Chemotherapy
Tolba, K. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-26568-3.00014-2

Authors: Ferris, R. L., Jaffee, E. M., & Ferrone, S.
Affiliations: Johns Hopkins University (US)
ORCID: Ferris, Robert L.
Jaffee, Elizabeth M.
Ferrone, Soldano
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2010-10-01
Volume: 28
Issue: 28
Pages: 4390-4399
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.27.6360
PMC: PMC2954137
OpenAlex: W2112887207
Cited by: 320
References: 122
Citations by year: 2026: 6 · 2025: 12 · 2024: 7 · 2023: 28 · 2022: 11 · 2021: 13 · 2020: 17 · 2019: 19 · 2018: 13 · 2017: 30 · 2016: 26 · 2015: 33 · 2014: 18 · 2013: 28 · 2012: 34
FWCI: 3.94
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Bristol-Myers Squibb
American Society of Clinical Oncology
National Cancer Institute (P50CA097190)
National Institute of Dental and Craniofacial Research (R01DE019727)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: antibody-dependent cellular cytotoxicity, Fc gamma receptor polymorphisms, tumor immune evasion, cell-mediated immunity, rituximab, trastuzumab, cetuximab, signaling pathway inhibition
MeSH terms: Animals, Antibodies, Monoclonal, Antigens, Neoplasm, Humans, Immunity, Cellular, Immunotherapy, Neoplasms, Receptors, Fc, Signal Transduction, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks